Breast Cancer Gene Test Spares Chemotherapy for Many

How the test changes treatment

A Breast Cancer Gene Test has helped most patients in a large trial safely skip chemotherapy, and new economic figures presented in Madrid suggest the approach could also save a health service millions of pounds a year. The findings, drawn from a randomized trial of more than four thousand participants, offer a clearer path for people facing one of the hardest decisions in early breast cancer care: whether gruelling treatment is truly needed.

Chemotherapy is routinely offered when early breast cancer has spread to nearby lymph nodes, because it lowers the chance of the disease returning. The drawback, clinicians have long warned, is that many people with the most common hormone-sensitive form of the disease gain little or no benefit, yet still endure fatigue, nausea, hair loss and a weakened immune system that raises the risk of infection. The Breast Cancer Gene Test addresses that dilemma by measuring gene activity in tumour tissue already removed during surgery or biopsy.

According to the university team behind the trial, about two-thirds of participants recorded a low score, indicating they could be treated safely with hormone therapy alone. That share translates, in the researchers' estimates, to roughly four thousand two hundred people a year across the country who might avoid chemotherapy if the test were offered to everyone eligible. The trial was run across a large network of hospitals in several countries, which strengthens confidence that the result is not confined to a single centre.

What the money figures show

The economic case was presented by a professor of medical oncology at a major European cancer congress in Madrid. Chemotherapy, on the trial's costing, ran to about five and a half thousand pounds per patient given it as standard treatment, once drugs, nursing and day-unit time, medicines for side effects and hospital admissions were counted. Using the test cut chemotherapy spending by a substantial sum for every patient tested, before the price of the test itself was factored in.

After allowing for the test price and for other costs, such as patients who skipped chemotherapy starting other treatments sooner, the researchers calculated a net saving of just over six hundred pounds for every patient tested within two years of diagnosis. Scaled across all eligible patients, that points to annual savings of around four million pounds. The chief investigator said the study only covers about the first two years from diagnosis, and that savings should grow over a longer horizon because rare, expensive late side effects of chemotherapy would also be avoided.

For patients, the value is not only financial. Skipping chemotherapy means avoiding weeks of side effects, time in hospital and time away from work and family, for people whose tumours show a low risk of spreading. For health services under constant budget pressure, the appeal is that a test which improves care can also release money for other patients. That combination is rare in cancer medicine, where better outcomes usually come with higher prices.

Who could benefit, and what comes next

Eligibility in the trial was specific: participants were aged forty or over, with hormone-sensitive disease that had either spread to a number of lymph nodes or formed a sizeable tumour. The test is already approved by the national health technology advisory body, but only for certain post-menopausal patients, with rules that differ from nation to nation. Expanding access would therefore require decisions by health systems, not just by individual doctors.

There are limits to what the figures prove. The savings estimate covers a two-year window, and longer follow-up will be needed to confirm that avoiding chemotherapy does not lead to higher costs or worse outcomes later. Some patients will still need chemotherapy, and the test is a guide to risk, not a guarantee for any individual. Doctors warn that the decision must remain personal, weighing tumour biology, other health conditions and patient preference.

The broader context helps explain why the result matters beyond one trial. Breast cancer is the most common cancer in women worldwide, and tens of thousands of women are diagnosed with invasive disease in the United Kingdom each year. Even a modest change in who receives chemotherapy therefore affects thousands of lives and a significant slice of cancer spending. Related health guidance for patients has also been in the news, including new advice on prescription drug apps, as regulators try to help people navigate a flood of medical information.

Researchers say the next steps are longer-term follow-up and wider discussion of funding and eligibility, so that the test reaches the patients most likely to benefit. For now, the message for patients facing this diagnosis is to ask whether the Breast Cancer Gene Test is available to them, and what their score would mean for their own treatment plan. Clinicians have also warned that online health myths are fooling more patients, making a conversation with a treating team, grounded in trial evidence, more important than ever.